The SULSA Assay Development Fund: accelerating translation of new biology from academia to pharma

Stuart P. McElroy (Lead / Corresponding author), Philip S. Jones, Denise V. Barrault

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)
182 Downloads (Pure)

Abstract

With industry increasingly sourcing preclinical drug discovery projects from academia it is important that new academic discoveries are enabled through translation with HTS-ready assays. However, many scientifically interesting, novel molecular targets lack associated high-quality, robust assays suitable for hit finding and development. To bridge this gap, the Scottish Universities Life Sciences Alliance (SULSA) established a fund to develop assays to meet quality criteria such as those of the European Lead Factory. A diverse project portfolio was quickly assembled, and a review of the learnings and successful outcomes showed this fund as a new highly cost-effective model for leveraging significant follow-on resources, training early-career scientists and establishing a culture of translational drug discovery in the academic community.

Original languageEnglish
Pages (from-to)199-203
Number of pages5
JournalDrug Discovery Today
Volume22
Issue number2
Early online date5 Oct 2016
DOIs
Publication statusPublished - Feb 2017

Fingerprint Dive into the research topics of 'The SULSA Assay Development Fund: accelerating translation of new biology from academia to pharma'. Together they form a unique fingerprint.

Cite this